When and Why Cytotoxicity Testing is Critical for Medical Device Safety and Compliance

Cytotoxicity refers to the potential of a material or substance to cause harmful effects at the cellular level. For medical devices, these risks must be carefully evaluated, especially when materials come into direct or indirect contact with human tissue. This makes cytotoxicity testing a vital part of ensuring biocompatibility.  

As an early-stage assessment, cytotoxicity testing is often the first test performed due to the test’s sensitive nature, quick turnaround time, and low cost.  Described in 10993-5, cytotoxicity tests help identify potential toxicity of medical devices and materials, helping product developers mitigate issues before entering more complex or costly phases of the biological assessment process.

Due to the test’s sensitivity, many medical device manufacturers utilize this test to screen materials and obtain a general indication of whether the broader suite of testing outlined in the 10993 series will pass or fail. Thus, understanding how and when to apply cytotoxicity testing is key to accelerating safe and compliant innovation.  

The endpoint of cytotoxicity needs to be addressed for all medical devices across all contact categories and durations. It’s especially important when evaluating:  

• Common times when testing is performed
• Initial approvals for regulatory agencies 
• Material screening 
• Changes in materials or processing of materials 
• Supplier changes 
• Assessing the biocompatibility of aged samples 
• Changes in the manufacturing process 
• Assessing colorants 
  
  

Cytotoxicity testing – Key compliance to ISO 10993  

Cytotoxicity testing is conducted to assess the potential cytotoxic effects of medical devices, materials, and their extracts on cultured mammalian cells. Depending on the device type and intended use, the test may be conducted using extract-based, direct-contact, or indirect-contact methods. 

When selecting a cytotoxicity test method, several factors must be considered to ensure scientifically valid and regulatory-compliant results. These include the chemical nature and solubility of the test article, the type of material (e.g., polymers, metals, coatings), and the intended clinical use, particularly the duration and type of patient contact.

The choice between qualitative and quantitative assessments (e.g., morphological grading vs. MTT or NRU assays) should align with the expected sensitivity and specificity needed for the material. Additionally, extraction conditions (e.g., temperature, time, and extraction vehicle) must reflect worst-case clinical exposure. Regulatory expectations, including adherence to ISO 10993-5, and historical biocompatibility data for similar materials, should also inform test selection. 

For regulatory professionals, cytotoxicity testing is a foundational element of demonstrating ISO 10993 compliance. For startups and product developers, it helps de-risk designs and prevent costly redesigns or submission delays.  

Importantly, while cytotoxicity is just one part of the ISO 10993 framework, it often determines the scope and necessity of further testing.

CYTOTOXICITY FAILURES 

In some cases, a device or material may exhibit a level of cytotoxic response that exceeds allowable limits defined by ISO 10993-5, resulting in a failing test outcome. Importantly, a failed cytotoxicity test does not automatically indicate that the device or material poses a clinical safety risk. Instead, it necessitates a systematic investigation to determine the root cause of the reactivity and to perform a safety assessment to evaluate the potential impact on patient safety.  

Common Device Types That Require Cytotoxicity Testing  

Cytotoxicity testing is applicable across a wide range of devices. Common examples include:  

• Implantable devices e.g., orthopaedic implants, cardiovascular stents, dental screws. These require rigorous testing due to prolonged and invasive body contact.  
• Surgical instruments and tools even reusable or transient-contact instruments require testing, especially after processing or sterilization.  
• Wound care products e.g., dressings, sutures, adhesive tapes  
• Materials in prolonged contact with compromised skin or tissue must demonstrate low cytotoxic potential.  
• Tubing and delivery systems e.g., IV sets, catheters, dialysis lines. These are often made from polymers that can leach additives or plasticizers.  
• Wearables and diagnostic sensors e.g., skin patches, biosensors. Long-term dermal exposure may raise concerns about irritation or local toxicity.  
• Packaging materials (in some cases) especially when they interact with the device or alter its biocompatibility.  

Even “low risk” devices may need testing if they contain new materials, surface treatments, or adhesives, or if the manufacturing process changes. Regulatory authorities often expect data to support safety under actual use conditions, especially for devices with prolonged or repeated contact.  

In Vitro vs. In Vivo Testing  

Under the ISO 10993 framework, biological evaluation follows a stepwise logic: begin with data that are readily available or easy to obtain and only escalate testing complexity when necessary. This makes it essential to distinguish between in vitro and in vivo methods. In vitro tests are conducted in a controlled laboratory environment using cultured cells. These methods are well-suited for detecting localized biological responses and are often the first choice due to their speed, reproducibility, and lower ethical burden.

In contrast, in vivo tests involve introducing the material or device into a living organism to assess systemic effects, long-term tolerability, or interactions that can’t be simulated in cell cultures.

Cytotoxicity testing, as defined by ISO 10993-5, is strictly an in vitro method. When combined with material characterization data, it may provide enough evidence to support regulatory submissions without additional animal testing.  

How to Assess the Need for Cytotoxicity Testing? Expert support from TÜV SÜD

Determining whether cytotoxicity testing is required depends on several factors, including material composition, intended use, and duration of body contact. While ISO 10993-1 provides the framework, expert guidance is often essential for interpreting risk and designing an efficient testing strategy.  

At TÜV SÜD, we support medical device manufacturers with:  

• Testing facilities (ISO 17025-accredited and GLP-compliant) 
• Regulatory support for EU, FDA, and global submissions  
• Dependable, compliant medical device testing with industry-leading expertise and turnaround times. 

The importance of engaging in a testing lab early in the process 

Early engagement with a qualified testing partner can prevent delays, reduce unnecessary testing, and help you align with evolving regulatory expectations.  
 

Comprehensive Medical Device Testing at ISO 17025 & GLP-Compliant Facility 

TÜV SÜD’s New Brighton lab, an ISO 17025-accredited and GLP-compliant third-party facility, supports every stage of your device’s lifecycle, from design and verification to regulatory submission and post-market support, offering a comprehensive portfolio of independent laboratory services backed by global regulatory expertise.  

Contact us now

Disclaimer: TÜV SÜD's certification and testing services are independent of each other and do not impact one another. Our certification services are delivered by TÜV SÜD's recognized Certification Bodies, while our testing services are conducted through TÜV SÜD Testing Labs